117 related articles for article (PubMed ID: 17325905)
1. Concomitant MYC and microRNA cluster miR-17-92 (C13orf25) amplification in human mantle cell lymphoma.
Rinaldi A; Poretti G; Kwee I; Zucca E; Catapano CV; Tibiletti MG; Bertoni F
Leuk Lymphoma; 2007 Feb; 48(2):410-2. PubMed ID: 17325905
[No Abstract] [Full Text] [Related]
2. MYC overexpression correlates with MYC amplification or translocation, and is associated with poor prognosis in mantle cell lymphoma.
Choe JY; Yun JY; Na HY; Huh J; Shin SJ; Kim HJ; Paik JH; Kim YA; Nam SJ; Jeon YK; Park G; Kim JE
Histopathology; 2016 Feb; 68(3):442-9. PubMed ID: 26100211
[TBL] [Abstract][Full Text] [Related]
3. Double-hit mantle cell lymphoma with MYC gene rearrangement or amplification: a report of four cases and review of the literature.
Setoodeh R; Schwartz S; Papenhausen P; Zhang L; Sagatys EM; Moscinski LC; Shao H
Int J Clin Exp Pathol; 2013; 6(2):155-67. PubMed ID: 23330001
[TBL] [Abstract][Full Text] [Related]
4. The miRNA-17∼92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation.
Rao E; Jiang C; Ji M; Huang X; Iqbal J; Lenz G; Wright G; Staudt LM; Zhao Y; McKeithan TW; Chan WC; Fu K
Leukemia; 2012 May; 26(5):1064-72. PubMed ID: 22116552
[TBL] [Abstract][Full Text] [Related]
5. Synergistic action of the microRNA-17 polycistron and Myc in aggressive cancer development.
Tagawa H; Karube K; Tsuzuki S; Ohshima K; Seto M
Cancer Sci; 2007 Sep; 98(9):1482-90. PubMed ID: 17608773
[TBL] [Abstract][Full Text] [Related]
6. Combined administration of rituximab and on 013105 induces apoptosis in mantle cell lymphoma cells and reduces tumor burden in a mouse model of mantle cell lymphoma.
Prasad A; Shrivastava A; Papadopoulos E; Kuzontkoski PM; Reddy MV; Gillum AM; Kumar R; Reddy EP; Groopman JE
Clin Cancer Res; 2013 Jan; 19(1):85-95. PubMed ID: 23124440
[TBL] [Abstract][Full Text] [Related]
7. Dysregulation of BMI1 and microRNA-16 collaborate to enhance an anti-apoptotic potential in the side population of refractory mantle cell lymphoma.
Teshima K; Nara M; Watanabe A; Ito M; Ikeda S; Hatano Y; Oshima K; Seto M; Sawada K; Tagawa H
Oncogene; 2014 Apr; 33(17):2191-203. PubMed ID: 23686310
[TBL] [Abstract][Full Text] [Related]
8. Non-Hodgkin's lymphomas with Burkitt-like cells are associated with c-Myc amplification and poor prognosis.
Mossafa H; Damotte D; Jenabian A; Delarue R; Vincenneau A; Amouroux I; Jeandel R; Khoury E; Martelli JM; Samson T; Tapia S; Flandrin G; Troussard X
Leuk Lymphoma; 2006 Sep; 47(9):1885-93. PubMed ID: 17065002
[TBL] [Abstract][Full Text] [Related]
9. An aggressive B-cell lymphoma with rearrangements of MYC and CCND1 genes: a rare subtype of double-hit lymphoma.
Durot E; Patey M; Luquet I; Gaillard B; Kolb B; Delmer A
Leuk Lymphoma; 2013 Mar; 54(3):649-52. PubMed ID: 22784333
[No Abstract] [Full Text] [Related]
10. MicroRNA signature obtained from the comparison of aggressive with indolent non-Hodgkin lymphomas: potential prognostic value in mantle-cell lymphoma.
Goswami RS; Atenafu EG; Xuan Y; Waldron L; Reis PP; Sun T; Datti A; Xu W; Kuruvilla J; Good DJ; Lai R; Church AJ; Lam WS; Baetz T; Lebrun DP; Sehn LH; Farinha P; Jurisica I; Bailey DJ; Gascoyne RD; Crump M; Kamel-Reid S
J Clin Oncol; 2013 Aug; 31(23):2903-11. PubMed ID: 23835716
[TBL] [Abstract][Full Text] [Related]
11. The over-expression of miR-34a fails to block DoHH2 lymphoma cell proliferation by reducing p53 via c-MYC down-regulation.
Rizzo M; Mariani L; Cavallini S; Simili M; Rainaldi G
Nucleic Acid Ther; 2012 Aug; 22(4):283-8. PubMed ID: 22830357
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-184 Deregulated by the MicroRNA-21 Promotes Tumor Malignancy and Poor Outcomes in Non-small Cell Lung Cancer via Targeting CDC25A and c-Myc.
Lin TC; Lin PL; Cheng YW; Wu TC; Chou MC; Chen CY; Lee H
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1532-9. PubMed ID: 25990966
[TBL] [Abstract][Full Text] [Related]
13. miR-223 is repressed and correlates with inferior clinical features in mantle cell lymphoma through targeting SOX11.
Zhou K; Feng X; Wang Y; Liu Y; Tian L; Zuo W; Yi S; Wei X; Song Y; Qiu L
Exp Hematol; 2018 Feb; 58():27-34.e1. PubMed ID: 29158064
[TBL] [Abstract][Full Text] [Related]
14. A microRNA polycistron as a potential human oncogene.
He L; Thomson JM; Hemann MT; Hernando-Monge E; Mu D; Goodson S; Powers S; Cordon-Cardo C; Lowe SW; Hannon GJ; Hammond SM
Nature; 2005 Jun; 435(7043):828-33. PubMed ID: 15944707
[TBL] [Abstract][Full Text] [Related]
15. BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas.
Beà S; Tort F; Pinyol M; Puig X; Hernández L; Hernández S; Fernandez PL; van Lohuizen M; Colomer D; Campo E
Cancer Res; 2001 Mar; 61(6):2409-12. PubMed ID: 11289106
[TBL] [Abstract][Full Text] [Related]
16. Mantle Cell Lymphoma With MYC Rearrangement: A Report of 17 Patients.
Hu Z; Medeiros LJ; Chen Z; Chen W; Li S; Konoplev SN; Lu X; Pham LV; Young KH; Wang W; Hu S
Am J Surg Pathol; 2017 Feb; 41(2):216-224. PubMed ID: 27776009
[TBL] [Abstract][Full Text] [Related]
17. EGFR/c-myc axis regulates TGFβ/Hippo/Notch pathway via epigenetic silencing miR-524 in gliomas.
Zhao K; Wang Q; Wang Y; Huang K; Yang C; Li Y; Yi K; Kang C
Cancer Lett; 2017 Oct; 406():12-21. PubMed ID: 28778566
[TBL] [Abstract][Full Text] [Related]
18. MYC and MiR: vicious circle.
Zhao X; Zhang X; Tao J
Oncotarget; 2013 Dec; 4(12):2168-9. PubMed ID: 24318653
[No Abstract] [Full Text] [Related]
19. The MYC/miR-17-92 axis in lymphoproliferative disorders: A common pathway with therapeutic potential.
Dal Bo M; Bomben R; Hernández L; Gattei V
Oncotarget; 2015 Aug; 6(23):19381-92. PubMed ID: 26305986
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-130a associates with ribosomal protein L11 to suppress c-Myc expression in response to UV irradiation.
Li Y; Challagundla KB; Sun XX; Zhang Q; Dai MS
Oncotarget; 2015 Jan; 6(2):1101-14. PubMed ID: 25544755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
